- Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
For: Non-Small Cell Lung Cancer · Colorectal Cancer · Advanced Solid TumorsUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I4T-MC-JVCY: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
This study looks at a new combination of treatments for advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). Researchers want to see if adding a drug called ramucirumab to erlotinib helps people live longer without their cancer getting worse, compared to erlotinib alone.
For: Metastatic Non-Small Cell Lung CancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib
This study looks at a new drug, LY2875358, combined with an existing lung cancer treatment, erlotinib, for people with a specific type of advanced non-small cell lung cancer. It compares this combination to using erlotinib alone to see if it helps patients live longer without their cancer growing.
For: Non-Small Cell Lung CancerSpain · Germany - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
For: Metastatic Non-Small Cell Lung CancerUnited States · Canada · France